Erweiterte Informationen für Ärzte

2020

Caroli P et al. 68Ga-PSMA-11 PET/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy.
Biomedicines 2020, 8, 536.

https://www.mdpi.com/2227-9059/8/12/536#cite

Abe T et al. Stereotactic body radiation therapy using CyberKnife for T1N0M0 lung cancer patients with severe pulmonary dysfunction.
J Radiat Res. 2020 Nov 16;61(6):903-907. doi: 10.1093/jrr/rraa075. PMID: 32880653; PMCID: PMC7674703.

https://pubmed.ncbi.nlm.nih.gov/32880653/

Dong B et al. Video-Assisted Thoracoscopic Lobectomy Versus Stereotactic Body Radiotherapy Treatment for Early-Stage Non-Small Cell Lung Cancer: A Propensity Score-Matching Analysis.
Front Oncol. 2020 Nov 10;10:585709. doi: 10.3389/fonc.2020.585709. PMID: 33244457; PMCID: PMC7683774.

https://pubmed.ncbi.nlm.nih.gov/33244457/

Poon I et al. Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis.
JAMA Netw Open. 2020 Nov 2;3(11):e2026312. doi: 10.1001/jamanetworkopen.2020.26312. PMID: 33196810; PMCID: PMC7670310.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670310/

Pan YX et al. Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis.
Front Oncol. 2020 Oct 29;10:1639. doi: 10.3389/fonc.2020.01639. PMID: 33194569; PMCID: PMC7658324.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658324/

Kalinauskaite G et al. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
PLoS One. 2020 Oct 21;15(10):e0240892. doi: 10.1371/journal.pone.0240892. PMID: 33085712; PMCID: PMC7577453.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577453/

Sogono P et al. Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases.
Int J Radiat Oncol Biol Phys. 2020 Oct 15:S0360-3016(20)34399-6. doi: 10.1016/j.ijrobp.2020.10.011. Epub ahead of print. PMID: 33069796; PMCID: PMC7560377.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560377/

Yamamoto T et al. Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival.
BMC Cancer. 2020 Oct 14;20(1):997. doi: 10.1186/s12885-020-07514-9. PMID: 33054721; PMCID: PMC7559191.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559191/

Dong B et al. Comparison of the outcomes of sublobar resection and stereotactic body radiotherapy for stage T1-2N0M0 non-small cell lung cancer with tumor size ≤ 5 cm: a propensity score matching analysis.
J Thorac Dis. 2020 Oct;12(10):5934-5954. doi: 10.21037/jtd-20-2367. PMID: 33209426; PMCID: PMC7656409.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656409/

Malone J et al. Adrenal oligometastasis cured with stereotactic ablative radiotherapy.
Radiol Case Rep. 2020 Sep 10;15(11):2266-2270. doi: 10.1016/j.radcr.2020.08.056. PMID: 32983297; PMCID: PMC7494600.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494600/

Li C et al. A meta-analysis comparing stereotactic body radiotherapy vs conventional radiotherapy in inoperable stage I non-small cell lung cancer.
Medicine (Baltimore). 2020 Aug 21;99(34):e21715. doi: 10.1097/MD.0000000000021715. PMID: 32846789; PMCID: PMC7447473.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447473/

Yoon SM et al.Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial.
Clin Mol Hepatol. 2020 Oct;26(4):506-515. doi: 10.3350/cmh.2020.0038. Epub 2020 Jul 10. PMID: 32646200; PMCID: PMC7641557.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641557/

Bei Y et al. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer in octogenarians and older: an alternative treatment.
J Radiat Res. 2020 Jul 6;61(4):586-593. doi: 10.1093/jrr/rraa027. PMID: 32383730; PMCID: PMC7336556.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336556/

Weykamp F et al. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Front Oncol. 2020 Jun 26;10:987. doi: 10.3389/fonc.2020.00987. PMID: 32676455; PMCID: PMC7333735.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333735/

Li J et al.Analysis of the efficacy, safety and survival factors of stereotactic body radiation therapy in patients with recurrence of pancreatic cancer.
Transl Oncol. 2020 Oct;13(10):100818. doi: 10.1016/j.tranon.2020.100818. Epub 2020 Jun 24. PMID: 32592902; PMCID: PMC7327753.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327753/

Seiten